BIO-B Bio-Rad Laboratories, Inc. - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
BIO-B Stock | Fundamental Analysis & Investment Insights
NYSE
Healthcare
Medical Devices
Current Price
Live
$312.75
52W High
$359.22
52W Low
$225.29
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$9.79B
P/E
N/A
ROE
-9.5%
Profit margin
-26.4%
Debt/Equity
0.21
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
68%
Analysis Accuracy
The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of just 2/9, indicating significant deterioration in fundamental performance. Despite a strong balance sheet (Current Ratio: 5.44, Debt/Equity: 0.21), the company is unprofitable (Profit Margin: -26.43%, ROE: -9.50%) and lacks meaningful valuation metrics due to negative earnings. While quarterly earnings have beaten estimates 3 out of 4 times recently, revenue growth is nearly flat (0.50% YoY), and long-term price performance remains deeply negative (-47.0% over 5 years). The absence of Altman Z-Score and Graham Number prevents a full value assessment, but current fundamentals do not support a bullish stance.
Key Strengths
Exceptionally strong liquidity position with Current Ratio of 5.44 and Quick Ratio of 3.62
Low leverage with Debt/Equity ratio of 0.21, well below sector average of 2.71
High gross margin of 52.36%, indicating pricing power or cost efficiency in core operations
Recent earnings surprises have been positive (3/4 beats, avg +13.83%)
Operating margin remains positive at 10.41% despite overall net losses
Key Risks
Very low Piotroski F-Score of 2/9 signals severe financial distress and deteriorating fundamentals
Negative profitability across net income (Profit Margin: -26.43%) and ROE (-9.50%)
Lack of P/E, Forward P/E, and Earnings Growth data suggests persistent unprofitability
Minimal revenue growth of only 0.50% YoY, below peer and sector averages
Long-term price underperformance: -47.0% over 5 years, significantly trailing peers
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
27
Weak
25
30
40
28
10
AI Verdict
Financially weak with unsustainable profitability and poor growth trajectory
Key drivers: Piotroski F-Score of 2/9, Negative net profitability, Near-zero revenue growth, Lack of analyst coverage and valuation metrics
Confidence
70%
Value
25/100
Ref P/E, PEG, Graham Number
Positives
- Price/Book of 1.25 is moderate, not excessively high
Watchpoints
- No P/E or Forward P/E due to negative earnings
- Graham Number unavailable, suggesting no defensive value support
- PEG Ratio and Intrinsic Value undefined
Future
30/100
Ref Growth rates
Positives
- Recent earnings beats suggest possible short-term upside
Watchpoints
- Revenue Growth (YoY) of only 0.50%
- No Q/Q earnings growth data, most recent EPS down -4.8% QoQ
- No analyst targets or forward guidance
Past
40/100
Ref Historical trends
Positives
- 3 out of 4 recent quarters beat earnings estimates
- Average earnings surprise of +13.83%
Watchpoints
- 5Y price return of -47.0%, indicating long-term underperformance
- 1Y return of -10.4%, still negative despite 6M rebound
Health
28/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Strong liquidity (Current Ratio: 5.44)
- Low Debt/Equity of 0.21
Watchpoints
- Piotroski F-Score of 2/9 indicates critical financial weakness
- ROE of -9.50% and Profit Margin of -26.43% reflect systemic unprofitability
- Altman Z-Score unavailable, increasing uncertainty
Dividend
10/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- Dividend Strength: 0/100
- No dividend yield or payout history
- Payout Ratio: 0.00%
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$312.75
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for BIO-B and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
BIO-B
Bio-Rad Laboratories, Inc.
Primary
|
-47.0% | -22.7% | -10.4% | +26.6% | +0.7% | +0.7% |
|
BAX
Baxter International Inc.
Peer
|
-72.4% | -52.4% | -37.8% | -31.6% | +3.8% | -1.3% |
|
AXSM
Axsome Therapeutics, Inc.
Peer
|
+146.1% | +162.6% | +79.0% | +84.4% | +21.0% | +4.9% |
|
MOH
Molina Healthcare, Inc.
Peer
|
-12.6% | -36.1% | -32.3% | +4.6% | +17.9% | +5.5% |
|
RGEN
Repligen Corporation
Peer
|
-27.1% | -12.7% | -0.5% | +39.4% | +3.2% | -2.9% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
N/A
PEG Ratio
N/A
P/B Ratio
1.25
P/S Ratio
3.83
EV/Revenue
3.29
EV/EBITDA
20.15
Market Cap
$9.79B
Profitability
Profit margins and return metrics
Profit Margin
-26.43%
Operating Margin
10.41%
Gross Margin
52.36%
ROE
-9.5%
ROA
1.57%
Growth
Revenue and earnings growth rates
Revenue Growth
+0.5%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.21
Low debt
Current Ratio
5.44
Strong
Quick Ratio
3.62
Excellent
Cash/Share
$52.59
Quarterly Earnings History
EPS performance vs analyst estimates
2019-08-01
$1.57
+18.9% surprise
2019-05-08
$1.65
+44.7% surprise
2019-02-28
$2.13
+14.5% surprise
2018-11-01
$0.91
-22.9% surprise
Healthcare Sector Comparison
Comparing BIO-B against 147 companies in the Healthcare sector
(10 bullish, 55 neutral, 82 bearish)
Return on Equity (ROE)
-9.5%
This Stock
vs
-52.77%
Sector Avg
-82.0%
(Below Avg)
Profit Margin
-26.43%
This Stock
vs
-20.78%
Sector Avg
+27.2%
(Superior)
Debt to Equity
0.21
This Stock
vs
6.16
Sector Avg
-96.6%
(Less Debt)
Revenue Growth
0.5%
This Stock
vs
137.39%
Sector Avg
-99.6%
(Slower)
Current Ratio
5.44
This Stock
vs
3.36
Sector Avg
+62.0%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
BIO-B
Bio-Rad Laboratories, Inc.
|
BEARISH | $9.79B | - | -9.5% | -26.4% | $312.75 | |
|
BAX
Baxter International Inc.
|
BEARISH | $10.2B | - | -4.7% | -3.1% | $19.84 | |
|
AXSM
Axsome Therapeutics, Inc.
|
BEARISH | $9.37B | - | -275.5% | -40.9% | $185.96 | |
|
MOH
Molina Healthcare, Inc.
|
BEARISH | $10.37B | 11.79 | 19.7% | 2.1% | $191.4 | |
|
RGEN
Repligen Corporation
|
NEUTRAL | $9.12B | 8101.0 | 0.1% | 0.2% | $162.02 |
Past News Coverage
Recent headlines mentioning BIO-B from our newsroom.
Newest → oldest
No matching news yet.